- Home
- ORGO vs DAVA Comparison
ORGO vs DAVA Comparison
Compare ORGO & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- DAVA
- Stock Information
- Founded
- ORGO 1985
- DAVA 2000
- Country
- ORGO United States
- DAVA United Kingdom
- Employees
- ORGO N/A
- DAVA N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- DAVA EDP Services
- Sector
- ORGO Health Care
- DAVA Technology
- Exchange
- ORGO Nasdaq
- DAVA Nasdaq
- Market Cap
- ORGO 539.1M
- DAVA 503.6M
- IPO Year
- ORGO N/A
- DAVA 2018
- Fundamental
- Price
- ORGO $5.14
- DAVA $6.48
- Analyst Decision
- ORGO Buy
- DAVA Buy
- Analyst Count
- ORGO 3
- DAVA 8
- Target Price
- ORGO $8.00
- DAVA $18.14
- AVG Volume (30 Days)
- ORGO 3.1M
- DAVA 1.4M
- Earning Date
- ORGO 11-06-2025
- DAVA 11-11-2025
- Dividend Yield
- ORGO N/A
- DAVA N/A
- EPS Growth
- ORGO N/A
- DAVA 58.26
- EPS
- ORGO N/A
- DAVA 0.25
- Revenue
- ORGO $465,218,000.00
- DAVA $1,015,391,026.00
- Revenue This Year
- ORGO $2.51
- DAVA N/A
- Revenue Next Year
- ORGO $25.45
- DAVA $3.81
- P/E Ratio
- ORGO N/A
- DAVA $25.41
- Revenue Growth
- ORGO 2.24
- DAVA 1.07
- 52 Week Low
- ORGO $2.61
- DAVA $6.03
- 52 Week High
- ORGO $7.08
- DAVA $34.94
- Technical
- Relative Strength Index (RSI)
- ORGO 50.25
- DAVA 34.00
- Support Level
- ORGO $5.09
- DAVA $6.24
- Resistance Level
- ORGO $5.83
- DAVA $6.45
- Average True Range (ATR)
- ORGO 0.50
- DAVA 0.33
- MACD
- ORGO -0.08
- DAVA -0.03
- Stochastic Oscillator
- ORGO 3.02
- DAVA 12.87
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.